Comparative Analysis of Systemic and Tumor Microenvironment Proteomes From Children With B-Cell Acute Lymphocytic Leukemia at Diagnosis and After Induction Treatment
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Frontiers in Oncology
Abstract
Among the childhood diseases, B-cell acute lymphocytic leukemia (B-ALL) is the most
frequent type of cancer. Despite recent advances concerning disease treatment, cytotoxic
chemotherapy remains the first line of treatment in several countries, and the modifications
induced by such drugs in the organism are still poorly understood. In this context, the
present study provided a comparative high-throughput proteomic analysis of the
cumulative changes induced by chemotherapeutic drugs used in the induction phase
of B-ALL treatment in both peripheral blood (PB) and bone marrow compartment (BM)
samples. To reach this goal, PB and BM plasma samples were comparatively analyzed by
using label-free proteomics at two endpoints: at diagnosis (D0) and the end of the
cumulative induction phase treatment (D28). Proteomic data was available via
ProteomeXchange with identifier PXD021584. The resulting differentially expressed
proteins were explored by bioinformatics approaches aiming to identify the main gene
ontology processes, pathways, and transcription factors altered by chemotherapy, as well
as to understand B-ALL biology in each compartment at D0. At D0, PB was characterized
as a pro-inflammatory environment, with the involvement of several downregulated
coagulation proteins as KNG, plasmin, and plasminogen. D28 was characterized
predominantly by immune response-related processes and the super expression of the
transcription factor IRF3 and transthyretin. RUNX1 was pointed out as a common
transcription factor found in both D0 and D28. We chose to validate the proteins
transthyretin and interferon-gamma (IFN-g) by commercial kits and expressed the results as PB/BM ratios. Transthyretin ratio was augmented after induction
chemotherapy, while IFN-g was reduced at the end of the treatment. Considering that
most of these proteins were not yet described in B-ALL literature, these findings added to
understanding disease biology at diagnosis and highlighted a possible role for
transthyretin and IFN-g as mechanisms related to disease resolution.